Other articles

ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate

ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate

The results of the STEP study were presented at the European Society of Cardiology (ESC) 2021 Congress! The main finding from this research was that an ideal target of 110 mmHg or at least <130 mmHg blood pressure (compared with a target of 130 mmHg or at least 150 mmHg) yielded an absolute risk reduction of composite events of

ESC 2021 | GREENNESS: Sorpresivo nuevo factor protector contra la enfermedad cardiovascular

ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease

What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could serve as a new protection against cardiovascular disease. During five years (the total research time), this study compared individuals who lived in the lowest tercile of “greenness” with those who lived in the highest tercile (i.e., those who

ESC 2021 | Empagliflozina en insuficiencia cardíaca con función deteriorada y preservada

ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction

The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death or hospitalization for heart failure (HF) in both patients with reduced and with preserved function. The primary endpoint (a composite of death and hospitalization for HF) was reduced by 21% on a relative basis with sodium/glucose cotransporter 2

Pacientes que no siguen nuestro consejo y sorpresivamente tienen menos eventos

Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead to multiple problems; in addition, over time, cognitive deterioration will make complicated drug management schemes even more difficult for patients to handle.  Aware of this problem, physicians often try to simplify schemes by discontinuing drugs, but what should

ACC 2021 | Revive la denervación renal de la mano del RADIANCE-HTN TRIO

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to this new study presented at ACC 2021 simultaneously published in the Lancet. Renal denervation reduces ambulatory daily systolic blood pressure by 8 mmHg vs 3 mmHg in the sham procedure branch.  This translates into a mean 4.5 mmHg

ACC 2021 | Sacubitril/valsartan no es superior al ramipril luego de un IAM

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in patients compared against ramipril. These data were provided by the PARADISE-MI presented today during the scientific sessions at ACC 2021. The combination sacubitril/valsartan had gathered prior evidence (basically from the PARADIGM-HF) for its superiority in terms of total

Beta Bloqueantes

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.  This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

Diastolic Pressure Could Play a Dirty Trick on Patients Treated for Hypertension

Having too low diastolic pressure could be linked to an increase in cardiovascular events (J-shape phenomenon). However, current guidelines suggest a target blood pressure under 130/80 mmHg with no lower limit for diastolic pressure. This paper, recently published in JAMA, sought to evaluate the J-shape phenomenon of diastolic pressure in treated patients who reached a target

Tratamiento médico óptimo

Medical Therapy Optimization Achieved Prior Clinical Trial

12 weeks prior the ORBITA randomization, medical therapy optimization of all antianginal medication was achieved.   Most importantly, optimization was well tolerated by all patients, with scarce adverse effects leading to therapy termination.  In clinical practice, there is skepticism towards achieving maximal dosage with a cost-effective therapy, good tolerance, adherence, and no drug-drug interaction.  The ORBITA

Saltearse el desayuno y riesgo cardiovascular

Regression of High-Risk Plaque with Lifestyle Changes

Diet and lifestyle intervention in addition to optimal medical therapy can slow down plaque building and even reduce plaque volume compared against optimal medical treatment (OTM) alone. Diet and lifestyle intervention are amongst the most important strategies to manage coronary artery disease. However, its direct impact on atherosclerosis remains unclear.  Atherosclerosis plaque building is associated

¿El alcohol es bueno, malo o neutro para la salud cardiovascular?

Might Alcohol Consumption Reduce Stroke?

A J shaped curve illustrating the link between alcohol consumption and ischemic stroke has been reported, suggesting that a certain amount of alcohol would be beneficial compared against absolute abstinence and excessive consumption.  In order to shed some light on this matter, this study looked at alcohol consumption patterns and their effect on stroke in